Rodriguez Murua S, Farez MF, Quintana FJ. The immune response in multiple sclerosis. Annu Rev Pathol. 2022;17:121–39.

Article  CAS  PubMed  Google Scholar 

Dendrou CA, Fugger L, Friese MA. Immunopathology of multiple sclerosis. Nat Rev Immunol. 2015;15:545–58.

Article  CAS  PubMed  Google Scholar 

Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med. 1998;338:278–85.

Article  CAS  PubMed  Google Scholar 

Wujek JR, Bjartmar C, Richer E, Ransohoff RM, Yu M, Tuohy VK, et al. Axon loss in the spinal cord determines permanent neurological disability in an animal model of multiple sclerosis. J Neuropathol Exp Neurol. 2002;61:23–32.

Article  PubMed  Google Scholar 

Dutta R, Trapp BD. Pathogenesis of axonal and neuronal damage in multiple sclerosis. Neurology. 2007;68:S22–31. discussion S43-54

Article  PubMed  Google Scholar 

Bebo B, Cintina I, LaRocca N, Ritter L, Talente B, Hartung D, et al. The economic burden of multiple sclerosis in the United States: estimate of direct and indirect costs. Neurology. 2022;98:e1810–e1817.

Article  PubMed  PubMed Central  Google Scholar 

Segal BM. Stage-specific immune dysregulation in multiple sclerosis. J Interferon Cytokine Res. 2014;34:633–40.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hu D, Notarbartolo S, Croonenborghs T, Patel B, Cialic R, Yang TH, et al. Transcriptional signature of human pro-inflammatory T(H)17 cells identifies reduced IL10 gene expression in multiple sclerosis. Nat Commun. 2017;8:1600.

Article  PubMed  PubMed Central  Google Scholar 

Mahad DH, Trapp BD, Lassmann H. Pathological mechanisms in progressive multiple sclerosis. Lancet Neurol. 2015;14:183–93.

Article  CAS  PubMed  Google Scholar 

Hauser SL, Cree BAC. Treatment of multiple sclerosis: a review. Am J Med. 2020;133:1380–90 e1382.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Segal BM. Modulation of the innate immune system: a future approach to the treatment of neurological disease. Clin Immunol. 2018;189:1–3.

Article  CAS  PubMed  Google Scholar 

Barbacid M. The Trk family of neurotrophin receptors. J Neurobiol. 1994;25:1386–403.

Article  CAS  PubMed  Google Scholar 

Huang EJ, Wilkinson GA, Farinas I, Backus C, Zang K, Wong SL, et al. Expression of Trk receptors in the developing mouse trigeminal ganglion: in vivo evidence for NT-3 activation of TrkA and TrkB in addition to TrkC. Development. 1999;126:2191–203.

Article  CAS  PubMed  Google Scholar 

Sahenk Z. Neurotrophins and peripheral neuropathies. Brain Pathol. 2006;16:311–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Richner M, Ulrichsen M, Elmegaard SL, Dieu R, Pallesen LT, Vaegter CB. Peripheral nerve injury modulates neurotrophin signaling in the peripheral and central nervous system. Mol Neurobiol. 2014;50:945–70.

Article  CAS  PubMed  Google Scholar 

Meier C, Parmantier E, Brennan A, Mirsky R, Jessen KR. Developing Schwann cells acquire the ability to survive without axons by establishing an autocrine circuit involving insulin-like growth factor, neurotrophin-3, and platelet-derived growth factor-BB. J Neurosci. 1999;19:3847–59.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sekimoto M, Tsuji T, Matsuzaki J, Chamoto K, Koda T, Nemoto K, et al. Functional expression of the TrkC gene, encoding a high affinity receptor for NT-3, in antigen-specific T helper type 2 (Th2) cells. Immunol Lett. 2003;88:221–6.

Article  CAS  PubMed  Google Scholar 

Yalvac ME, Arnold WD, Braganza C, Chen L, Mendell JR, Sahenk Z. AAV1.NT-3 gene therapy attenuates spontaneous autoimmune peripheral polyneuropathy. Gene Therapy 2015;23:95–102.

Sahenk Z, Galloway G, Clark KR, Malik V, Rodino-Klapac LR, Kaspar BK, et al. AAV1.NT-3 gene therapy for Charcot-marie-tooth neuropathy. Mol Ther. 2014;22:511–21.

Article  CAS  PubMed  Google Scholar 

Yalvac ME, Amornvit J, Chen L, Shontz KM, Lewis S, Sahenk Z. AAV1.NT-3 gene therapy increases muscle fiber diameter through activation of mTOR pathway and metabolic remodeling in a CMT mouse model. Gene Therapy 2018;25:129–38.

Ozes B, Myers M, Moss K, McKinney J, Ridgley A, Chen L, et al. AAV1.NT-3 gene therapy for X-linked Charcot-Marie-Tooth neuropathy type 1. Gene Therapy 2021;29:127–37.

Ozes B, Moss K, Myers M, Ridgley A, Chen L, Murrey D, et al. AAV1.NT-3 gene therapy in a CMT2D model: phenotypic improvements in Gars(P278KY/+) mice. Brain Commun. 2021;3:fcab252.

Article  PubMed  PubMed Central  Google Scholar 

Ozes B, Tong L, Myers M, Moss K, Ridgley A, Sahenk Z. AAV1.NT-3 gene therapy prevents age-related sarcopenia. Aging. 2023;15:1306–29.

CAS  PubMed  PubMed Central  Google Scholar 

Sahenk Z, Nagaraja HN, McCracken BS, King WM, Freimer ML, Cedarbaum JM, et al. NT-3 promotes nerve regeneration and sensory improvement in CMT1A mouse models and in patients. Neurology. 2005;65:681–9.

Article  CAS  PubMed  Google Scholar 

Beutner C, Lepperhof V, Dann A, Linnartz-Gerlach B, Litwak S, Napoli I, et al. Engineered stem cell-derived microglia as therapeutic vehicle for experimental autoimmune encephalomyelitis. Gene Ther. 2013;20:797–806.

Article  CAS  PubMed  Google Scholar 

Barres BA, Raff MC, Gaese F, Bartke I, Dechant G, Barde YA. A crucial role for neurotrophin-3 in oligodendrocyte development. Nature. 1994;367:371–5.

Article  CAS  PubMed  Google Scholar 

Coelho RP, Yuelling LM, Fuss B, Sato-Bigbee C. Neurotrophin-3 targets the translational initiation machinery in oligodendrocytes. Glia. 2009;57:1754–64.

Article  PubMed  PubMed Central  Google Scholar 

Barres BA, Schmid R, Sendnter M, Raff MC. Multiple extracellular signals are required for long-term oligodendrocyte survival. Development. 1993;118:283–95.

Article  CAS  PubMed  Google Scholar 

Miller SD, Karpus WJ. Experimental autoimmune encephalomyelitis in the mouse. Curr Protoc Immunol. 2007;Chapter 15:15 11 11–15 11 18.

Google Scholar 

Khan N, Gordon R, Woodruff TM, Smith MT. Antiallodynic effects of alpha lipoic acid in an optimized RR-EAE mouse model of MS-neuropathic pain are accompanied by attenuation of upregulated BDNF-TrkB-ERK signaling in the dorsal horn of the spinal cord. Pharmacol Res Perspect. 2015;3:e00137.

Article  PubMed  PubMed Central  Google Scholar 

Toscano MG, Delgado M, Kong W, Martin F, Skarica M, Ganea D. Dendritic cells transduced with lentiviral vectors expressing VIP differentiate into VIP-secreting tolerogenic-like DCs. Mol Ther. 2010;18:1035–45.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Attia Z, Rowe JC, Kim E, Varikuti S, Steiner HE, Zaghawa A, et al. Inhibitors of elastase stimulate murine B lymphocyte differentiation into IgG- and IgA-producing cells. Eur J Immunol. 2018;48:1295–301.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kim E, Attia Z, Woodfint RM, Zeng C, Kim SH, Steiner HE, et al. Inhibition of elastase enhances the adjuvanticity of alum and promotes anti-SARS-CoV-2 systemic and mucosal immunity. Proc Natl Acad Sci USA. 2021;118:e2102435118.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yalvac ME, Arnold WD, Hussain SR, Braganza C, Shontz KM, Clark KR, et al. VIP-expressing dendritic cells protect against spontaneous autoimmune peripheral polyneuropathy. Mol The